Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 23Neutropenia 22Neoplasms 7Chemotherapy-induced Neutropenia 7Lymphoma, Non-Hodgkin 6Ovarian Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Lymphoma 3Fever 3Febrile Neutropenia 3Colorectal Neoplasms 3Rectal Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Previously Treated Non Small Cell Lung Cancer 1Neuroectodermal Tumors, Primitive, Peripheral 1Malignant Solid Tumors 1Lymphoma, T-Cell, Peripheral 1Leukemia, Myeloid, Acute 1

Interventions

robatumumab 1pegfilgrastim 1omburtamab I-131 1lenvatinib 1exatecan 1cixutumumab 1amino-acid, glucose, and electrolyte solution 1Temozolomide 1Irinotecan 1Fentanyl 1FANG vaccine 1Everolimus 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neuroectodermal Tumors, Primitive, Peripheral × pegfilgrastim × Clear all
NCT01585649 2016-05-18

PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1 Completed
21 enrolled
Sarcoma

Rhabdomyosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡